HBC(SH:603077) Xin Lang Cai Jing·2025-10-29 03:05Group 1 - The core viewpoint of the news is that Hebang Biotechnology (603077.SH) has reported its Q3 2025 results, highlighting significant institutional investor holdings [1] - As of October 28, 2025, a total of 10 institutional investors hold shares in Hebang Biotechnology, with a combined holding of 2.823 billion shares, representing 31.97% of the company's total equity [1] - The top ten institutional investors include notable entities such as Sichuan Hebang Investment Group Co., Ltd. and Huatai Securities Co., Ltd., with their combined holding ratio increasing by 0.27 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, the Chemical ETF, increased its holdings by 0.95% compared to the previous period [2] - One public fund, the Southern CSI 500 ETF, reported a slight decrease in holdings [2] - Five new public funds were disclosed this period, including E Fund Credit Benefit Bond A and others, while 140 public funds were not disclosed this period, including several CSI 500 ETFs [2]